Convatec Group Plc · LSE:CTEC
Convatec — Q1 2018 Earnings Presentation
15 slides from Convatec's earnings presentation, May 2, 2018
Slide 1: Q1 2018 Trading Update
Q1 2018 Trading Update 2 MAY 2018 0
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) is being furnished to each recipient in connection with ConvaTec Group Plc (“ConvaTec” and, together with its subsidiaries, the “Group”) and has been prepared from publicly available information. For the purposes of this notice, “Presentation” means
Slide 3: Q1 2018 Key points
Q1 2018 Key points • Group revenue +3.7%1 (organic), +7.5%2 (constant currency), +13.7% (reported) • A solid start to the year in Q1 • Ostomy Care and Advanced Wound Care performance reflects ongoing impact of supply constraints which arose last year, as previously discussed • Progress across the Gr
Slide 4: Franchise Results Overview
Franchise Results Overview Q1 2018 Reported revenue ($’m) Organic growth1,2 Advanced Wound Care 147.1 +2.2% Ostomy Care 128.0 (2.5)% Continence & Critical Care 108.4 +5.6% Infusion Devices 74.7 +16.3% Total Revenue 458.2 +3.7% 1 Organic growth presents year on year growth at constant exchange rates,
Slide 5: Advanced Wound Care
Advanced Wound Care Good growth in foam and silver, ongoing recovery of lost accounts Reported revenue ($m) 157.8 147.9 147.1 133.7 138.4 • +2.2%1 organic revenue growth • Foam and AQUACEL® Ag+ delivered good growth Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1 FY18 • AvelleTM revenues continue to build • US p
Slide 6: Ostomy Care
Ostomy Care Positive me+TM momentum, ongoing impact of supply constraints Reported revenue $’m Reported revenue ($m) 142.2 132.9 132.1 128.0 • -2.5%1 organic revenue growth 121.8 • ongoing impact of supply constraints and consequent patient loss Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1 FY18 • Good progres
Slide 7: Continence & Critical Care
Continence & Critical Care Strong HDG performance Reported revenue $’m Reported revenue ($m) 111.6 108.4 96.2 89.6 • +5.6% organic1 85.5 • $15.9 million2 contribution from Woodbury Holdings and J&R Medical Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1 FY18 • Strong performance by HDG and GentleCath™ in US • Gr
Slide 8: Infusion Devices
Infusion Devices Good underlying growth boosted by significant tailwinds Reported revenue $’m Reported revenue ($m) 76.2 74.7 67.3 69.3 62.1 • Revenue growth of 16.3%1 • Boosted by customer inventory increase and customer voluntary product recall Q1 FY17 Q2 FY17 Q3 FY17 Q4 FY17 Q1 FY18 • Expect full
Slide 9: Commercial and operational objectives for 2018
Commercial and operational objectives for 2018 Commercial • Address US post-acute channel • Continue to increase momentum with foam, silver and AvelleTM • Continue to drive successful Ostomy strategy Operational • Complete optimisation of Haina • Develop plans for new projects • Re-launch productivi
Slide 10: Q1 2018 Summary
Q1 2018 Summary • Solid start to the year • Group performance in line with expectations • Strong performance from Infusion Devices and Continence & Critical Care • Ostomy Care reflects ongoing impact from supply constraints and consequent patient loss • Advanced Wound Care – growth in foam and silve
Slide 11: Q&A
y Q&A fini? Foamlite QB Avelle’ aguaces Gantlecath’ ers" ESTEEM © Flex Convex 10 @ ConvaTec
Slide 12: Appendix
Appendix 11
Slide 13: Quarterly Revenue Performance
Quarterly Revenue Performance Quarterly reported revenues by franchise Organic1 growth rate by franchise 2017 2018 2017 2018 $m Q1 Q2 Q3 Q4 Q1 % Q1 Q2 Q3 Q4 Q1 AWC 133.7 138.4 147.9 157.8 147.1 AWC 4.2 2.6 1.4 2.3 2.2 Ostomy Ostomy 121.8 132.9 132.1 142.2 128.0 1.1 3.6 (1.8) 0.3 (2.5) Care Care C&CC
Slide 14: Revenues by Geography
Revenues by Geography Q1 2018 reported Reported growth Organic growth1 ($m) Americas 234.3 15.8% 8.1% EMEA 192.2 12.6% (0.9)% APAC 31.7 5.7% 0.3% Group 458.2 13.7% 3.7% 1 Organic growth presents year on year growth at constant exchange rates, excluding M&A activities 13
Slide 15: FX rates
FX rates Q1 2018 Average Q1 2017 Average USD/GBP 1.39 1.24 USD/EUR 1.23 1.07 14